Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.49B | 2.95B | 3.61B | 3.61B | 3.44B |
| Total Other Revenue | 183.90M | 81.90M | 179.40M | 114.20M | 104.50M |
| Total Revenue | 3.68B | 3.03B | 3.79B | 3.72B | 3.55B |
| Cost of Revenue | 1.95B | 1.79B | 1.98B | 1.76B | 1.68B |
| Gross Profit | 1.72B | 1.24B | 1.81B | 1.96B | 1.87B |
| SG&A Expenses | 634.20M | 633.00M | 792.20M | 714.40M | 758.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.59B | 2.42B | 2.77B | 2.48B | 2.44B |
| Operating Income | 1.09B | 604.00M | 1.02B | 1.24B | 1.11B |
| Income Before Tax | 1.52B | 905.00M | 958.10M | 1.49B | 1.63B |
| Income Tax Expenses | 127.10M | 96.30M | 40.40M | 152.40M | 195.80M |
| Earnings from Continuing Operations | 1.39B | 808.70M | 917.70M | 1.34B | 1.43B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.39B | 808.70M | 917.70M | 1.34B | 1.43B |
| EBIT | 1.09B | 604.00M | 1.02B | 1.24B | 1.11B |
| EBITDA | 1.22B | 730.90M | 1.15B | 1.37B | 1.23B |
| EPS Basic | 13.24 | 7.58 | 8.53 | 12.40 | 13.25 |
| Normalized Basic EPS | 7.61 | 4.55 | 6.97 | 8.23 | 7.37 |
| EPS Diluted | 12.81 | 7.27 | 8.07 | 11.54 | 12.41 |
| Normalized Diluted EPS | 7.36 | 4.37 | 6.59 | 7.65 | 6.90 |
| Average Basic Shares Outstanding | 105.10M | 106.70M | 107.60M | 108.10M | 108.10M |
| Average Diluted Shares Outstanding | 108.60M | 111.20M | 113.80M | 116.20M | 115.40M |
| Dividend Per Share | 0.88 | 0.88 | -- | -- | -- |
| Payout Ratio | 6.65% | 11.60% | -- | -- | -- |